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Summary
Background: Coronary artery disease (CAD) is highly prevalent and strongly associ-
ated with adverse outcomes in patients with chronic kidney disease (CKD). Recent
data demonstrate that estimated glomerular ﬁltration rate (eGFR) is more useful
than serum creatinine as a predictor of outcomes.
Methods and results: We investigated the clinical signiﬁcance of eGFR-deﬁned
CKD in Japanese patients with CAD. In 702 consecutive patients with suspected
CAD who underwent coronary angiography, CKD (eGFR <60ml/min/1.73m2) was
present in 345 patients (49%). The eGFR value was lower in patients with multi-
vessel coronary artery disease compared to patients with no signiﬁcant stenosis
(59± 24ml/min/1.73m2 vs 66± 21ml/min/1.73m2, p < 0.01). During a follow-up
period of 36 months, secondary events that included all-cause death and cardiovas-
cular events requiring hospitalization occurred in 114 (16%) patients. Multivariate
analysis using a Cox proportional hazards model showed that CKD [relative risk
(RR) 1.707, 95%CI, 1.170—2.489; p = 0.004] along with diabetes (RR, 1.684, 95%CI,
1.262—2.386; p = 0.008) were independent predictors of secondary events.
Conclusions: eGFR-deﬁned CKD is an important predictor of secondary outcomes in
Japanese patients with CAD. Anti-atherosclerotic therapies under eGFR monitoring
to consider renoprotection would be an important strategy to improve long-term
prognosis in Japanese CAD patients.
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Table 1 Baseline characteristics.
Age (years) 68.8± 11.1
Gender (M/F) 494/208
Basal disease
Angina pectoris 294 (42%)
Old myocardial infarction 345 (49%)
Vasospastic angina 31 (4%)
Chest pain syndrome (control) 32 (5%)
Affected vessels
No stenosis 204 (29%)
Single vessel disease 198 (28%)
Multi-vessel disease 300 (43%)
Prior coronary angioplasty 339 (48%)
Prior coronary artery bypass surgery 139 (20%)
Therapy
Medication 466 (66%)
Coronary angioplasty 197 (28%)
Coronary artery bypass surgery 39 (6%)
Risk factor
Hypertension 577 (82%)
Diabetes mellitus 335 (48%)
Dyslipidemia 499 (71%)
Smoking 412 (59%)
Fasting blood glucose (mg/dl) 142± 73
LDL-cholesterol (mg/dl) 103± 26
HDL-cholesterol (mg/dl) 47± 13
Triglyceride (mg/dl) 149± 96
Medication
Statin 455 (65%)
RAS inhibitors 446 (64%)
Calcium channel blocker 306 (44%)
 Blocker 273 (39%)
Aspirin 623 (89%)
eGFR (ml/min/1.73m2) 61± 23
CKD 345 (49%)
LDL, low-density lipoprotein; HDL, high-density lipoprotein;
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hhronic kidney disease and coronary artery disease
nd-stage renal disease, especially in patients
ndergoing hemodialysis [1,2]. Even mild renal dys-
unction as indicated by proteinuria alone has been
hown to be an independent risk factor for the onset
f cardiovascular disease in the general popula-
ion [3]. In spite of disease severity or choice of
herapeutic strategy, such as coronary angioplasty,
oronary artery bypass surgery, or medical ther-
py, the presence of renal dysfunction was linked
o an increased risk of mortality in CAD patients
4].
Serum creatinine is generally thought to be
poor indicator of renal function. In contrast,
lomerular ﬁltration rate (GFR) is a more accu-
ate measure of renal function [5] and identiﬁes
atients with mild renal impairment despite nor-
al or nearly normal creatinine levels. Estimated
FR (eGFR) is a powerful predictor of outcome
n patients with acute myocardial infarction and
s more useful for this purpose than serum cre-
tinine [6]. Likewise, in recent large population
tudies, eGFR was a strong predictor of cardiovas-
ular events [7—9]. Chronic kidney disease (CKD), a
isease entity including mild to end-stage renal dis-
ases due to any etiology [5], was recently deﬁned
s an eGFR <60ml/min/1.73m2 and/or the pres-
nce of proteinuria. Very recently, eGFR-deﬁned
KD was assessed as a predictor of cardiovascu-
ar prognosis from the 10-year follow-up data of
he Framingham Heart Study original cohort [10].
here are, however, limited data on the prognos-
ic utility of eGFR for secondary events in patients
ith CAD. In addition, there are no established data
egarding an association between CKD and CAD in
apan.
This study was designed to establish the clinical
igniﬁcance of eGFR-deﬁned CKD, as a risk factor
nd a predictor of secondary outcomes in Japanese
atients with stable CAD.
ethods
atients
he study enrolled 702 consecutive patients [494
en and 208 women, aged 69± 11 (range: 36—93,
edian: 71) years]. All patients underwent diag-
ostic coronary angiography from March 2005 to
une 2007 for suspicion of chronic CAD and were
ollowed-up for a maximum period of 36 months
12—36 months). They included 639 patients with
ngiographically veriﬁed atherosclerotic CAD (sta-
le angina pectoris, 294 patients; old myocardial
nfarction, 345 patients), 31 patients with vasospas-
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pRAS, renin-angiotensin system; eGFR, estimated glomerular
ﬁltration rate; CKD, chronic kidney disease.
ic angina who had no signiﬁcant organic coronary
rtery lesions but a positive acetylcholine test,
nd 32 patients with chest pain syndrome that
erved as control subjects (Table 1). Patients
ere excluded who had had acute myocardial
nfarction within the previous 3 months, or unsta-
le angina with an attack of chest pain within
he previous month. Patients with idiopathic car-
iomyopathy, valvular heart disease, congenital
eart disease or other non-ischemic heart dis-
ase, and patients undergoing hemodialysis were
lso excluded. The local institutional review
oard approved the study protocol, and writ-
en informed consent was obtained from each
atient.
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Evaluation of angiographic ﬁndings
The angiographic ﬁndings were assessed by an
investigator who was unaware of the study design.
Coronary angiograms were visually assessed for all
of the atherosclerotic coronary lesions. According
to the classiﬁcation of the American Heart Associa-
tion, the percent diameter stenosis was evaluated
for each lesion and the lesion location was assessed.
We assessed the number of affected vessels as 0,
1, 2, and 3, considering that >50% diameter steno-
sis was a signiﬁcant atherosclerotic coronary lesion.
Patients were divided into 3 groups based on the
affected vessel number as no signiﬁcant organic
stenosis (0 vessel) including vasospastic angina and
controls, single vessel disease (1 vessel), and multi-
vessel disease (2 or 3 vessels).
Risk factor assessment
Conventional risk factors such as hyperten-
sion, diabetes mellitus, dyslipidemia, or smoking
habits were assessed as categorical variables
via the patients’ history and medical examina-
tions. Fasting peripheral blood was collected early
in the morning prior to coronary angiography.
The levels of fasting blood glucose, low-density
lipoprotein (LDL)-cholesterol, high-density lipopro-
tein (HDL)-cholesterol, and triglycerides were
measured in the sampled blood. Receiving anti-
diabetic agents or a fasting blood glucose level
≥140mg/dl were included in diabetes. Receiv-
ing lipid lowering drugs, an LDL-cholesterol level
≥100mg/dl, HDL-cholesterol level ≤40mg/dl, or
triglyceride level ≥150mg/dl was deﬁned as
dyslipidemia. Serum creatinine level was also
measured using an enzymatical method, and the
GFR was estimated from the Japanese Soci-
ety of Nephrology CKD Practice Guide: eGFR
(ml/min/1.73m2) = 194× (serum creatinine level
[mg/dl])−1.094 × (age [y])−0.287. The product of this
equation was multiplied by a correction factor
of 0.739 for women. According to the eGFR val-
ues (ml/min/1.73m2), patients were classiﬁed into
5 stages as follows: stage I, eGFR≥ 90; stage II,
90 > eGFR≥ 60; stage III, 60 > eGFR≥ 30; stage IV,
30 > eGFR≥ 15; and stage V, 15 > eGFR. Stages III—V
(eGFR < 60ml/min/1.73m2) were deﬁned as CKD.
Outcomes during follow-upPatient outcomes over a 36-month follow-up period
were identiﬁed via a clinic medical examination
or telephone contact. Information regarding poten-
tial events was conﬁrmed based on the data
source, including charts of hospital days, discharge
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etters, analysis of coronary angiograms or elec-
rocardiograms, and laboratory data. The endpoint
as deﬁned as occurrence of a secondary event
hat included all-cause death, hospitalization for
onfatal myocardial infarction, refractory angina
ectoris, repeated revascularization after coronary
ngioplasty or coronary artery bypass surgery, new
evascularization during medical follow-up, heart
ailure, serious arrhythmia, nonfatal cerebrovascu-
ar accident, and others.
tatistical analysis
ata are expressed as the mean± SD. Comparisons
etween two groups were assessed by an unpaired
-test for continuous variables and a chi-square test
or categorical variables. Multi-group comparisons
ere performed by one-way analysis of variance
ANOVA) followed by a post hoc Fisher PLSD test. A
ox proportional hazards model was used for pre-
icting the patients’ secondary outcomes, in which
ge, risk factors and medications were entered as
ndependent variables. Variables with a p value
s <0.05 in univariate analyses were also entered
nto the multivariate analysis. Kaplan—Meier sur-
ival curves were compared between patients with
r without CKD using the log rank test. In addition,
n patients with CKD, Kaplan—Meier survival curves
ere compared between the patients with and
ithout the use of statins, renin-angiotensin sys-
em (RAS) inhibitors such as angiotensin-converting
nzyme inhibitors (ACEIs) or angiotensin receptor
lockers (ARBs), calcium channel blockers and 
lockers at baseline. A p value <0.05 was considered
igniﬁcant.
esults
revalence of CKD in patients with CAD
aseline characteristics of all 702 patients are
hown in Table 1. Medications shown are base-
ine ones that had already been prescribed at
he time of coronary angiography or those that
ere newly prescribed after angiography. The
alue of eGFR was 61± 23ml/min/1.73m2, and
KD was present in 345 patients (49%). Among
atient groups classiﬁed based on basal diseases
uch as stable angina pectoris (n = 294), old myocar-
ial infarction (n = 345), vasospastic angina (n = 31),
nd chest pain syndrome (n = 32; controls), there
ere no signiﬁcant differences in the eGFR values
61± 23, 63± 23, 60± 22, 60± 24ml/min/1.73m2,
espectively) (Fig. 1, left). In comparisons among
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Figure 1 Estimated glomerular ﬁltration rate (eGFR) in each basal disease state (left) and in number of affected
coronary vessels (right). There were no signiﬁcant differences in the values among control, vasospastic angina, stable
angina pectoris, and old myocardial infarction. The value was higher in patients with multi-vessel disease, compared
to patients with no signiﬁcant stenosis.
Table 2 Comparisons of age and conventional risk factors in patients with and without CKD.
Non-CKD CKD P-value
(n = 357) (n = 345)
Age 67± 11 70± 10 0.001
Hypertension 287 (80%) 290 (84%) 0.581
Diabetes 156 (44%) 179 (52%) 0.422
Dyslipidemia 274 (77%) 225 (65%) 0.086
Smoking 196 (55%) 216 (63%) 0.314
Fasting blood glucose (mg/dl) 142± 80 140± 63 0.697
LDL-cholesterol (mg/dl) 105± 25 99± 27 0.094
HDL-cholesterol (mg/dl) 48± 13 45± 12 0.002
104 147± 86 0.527
.2 1.5± 1.2 0.027
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in 114 (16%) of all patients. In these 114 patients,
death from any cause occurred in 12 (11%), nonfatal
myocardial infarction in 3 (3%), refractory angina
pectoris (including patients with revascularization)Triglycerides (mg/dl) 152±
Number of affected vessels 1.3± 1
he 3 patient groups of no signiﬁcant organic
tenosis, single vessel disease, and multi-vessel
isease, the eGFR was lower in patients with
ulti-vessel disease than in patients with no
igniﬁcant stenosis (59± 24ml/min/1.73m2 vs
6± 21ml/min/1.73m2, p < 0.01) (Fig. 2, right).
able 2 shows comparisons of age and conven-
ional risk factors between patient groups with
nd without CKD. Patients with CKD were older
nd showed lower HDL-cholesterol level, compared
o patients without CKD. The number of affected
oronary vessels was greater in patients with CKD
han in patients without CKD (1.5± 1.2 vs 1.3± 1.2,
< 0.05).
ong-term outcome in patients with CADn a total of 702 patients, 197 (28%) underwent
oronary angioplasty, 39 (6%) underwent coronary
rtery bypass surgery, and the remaining 466 (66%)
ere managed medically (Table 1). During a follow-
p period of 36 months, secondary events occurred
Figure 2 Cumulative event rate in each patient group
for 5 stages classiﬁed based on eGFR value. The event
rate was 12%, 12%, 18%, 29%, and 47% in stages I, II, III,
IV, and V, respectively.
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Figure 3 Univariate analyses for the prediction of secondary events by a Cox proportional hazards model. Diabetes
mellitus, no statin administration and CKD were signiﬁcant predictors. These 3 parameters were entered into the
multivariate analysis. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CKD, chronic
kidney disease.
Table 3 Multivariate analysis for predicting secondary events by a Cox proportional hazards model.
Relative risk 95% Conﬁdence interval P-value
Diabetes; yes 1.684 1.262—2.386 0.008
4
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bStatin; no 1.572
CKD; yes 1.707
in 23 (20%), revascularization without symptoms
in 54 (47%), heart failure in 9 (8%), cerebrovas-
cular accident in 3 (3%), arrhythmia in 4 (3%),
and others including aortic or peripheral artery
diseases in 6 (6%). No patients required the ini-
tiation of hemodialysis during follow-up. In each
patient group for 5 stages classiﬁed based on
eGFR values, the cumulative event rate was 12%
(9/76), 12% (35/287), 18% (54/300), 29% (8/28) and
1
(
(
n
Figure 4 Kaplan—Meier survival curves compared between p
(left) and between patients with and without statin use in 345
event rate was 11% higher in patients with than without CK
RAS inhibitors was associated with a 24% reduction in the
renin-angiotensin system inhibitor.0.873—2.226 0.436
1.170—2.489 0.004
7% (8/17) in stages I, II, III, IV, and V, respec-
ively (Fig. 2), and consequently 20% (70/345) in
atients with CKD and 12% (44/357) in patients
ithout CKD. Univariate analysis showed that dia-
etes mellitus [relative risk (RR) 1.754; 95%CI,
.204—2.555; p = 0.003], no statin administration
RR, 1.468; 95%CI, 1.011—2.119; p = 0.043) and CKD
RR, 2.56; 95%CI, 1.626—4.072; p = 0.001) were sig-
iﬁcant predictors of secondary events (Fig. 3).
atients with and without CKD in 702 overall CAD patients
patients with CAD along with CKD (right). The cumulative
D. In patients with CKD, the use of statins along with
event rate, compared to no use of both agents. RASI,
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chronic kidney disease and coronary artery disease
ultivariate analysis showed that CKD (RR, 1.707;
5%CI, 1.170—2.489; p = 0.004) along with diabetes
RR, 1.684; 95%CI, 1.262—2.386; p = 0.008) were
ndependent predictors (Table 3). Kaplan—Meier
urvival curves showed that the cumulative event
ate was 11% higher in patients with than with-
ut CKD (log rank test, p = 0.006) (Fig. 4, left). In
45 patients with CAD along with CKD, baseline use
f statins, RAS inhibitors (ACEIs or ARBs), calcium
hannel blockers, or  blockers at the time of coro-
ary angiography was not solely associated with
econdary outcomes. However, the use of statins
long with RAS inhibitors was associated with a 24%
eduction in the event rate, compared to no use of
oth agents (log rank test, p = 0.012) (Fig. 4, right).
iscussion
n the present study, we demonstrated the preva-
ence of CKD in Japanese patients with chronic CAD
rom several perspectives. First, eGFR-deﬁned CKD
as present in more than 50% of the population
ith chronic CAD undergoing diagnostic coronary
ngiography, even after exclusion of hemodia-
yzed patients. Next, the eGFR value was lower
n patients with multi-vessel CAD, compared to
atients without organic coronary artery steno-
is including chest pain syndrome and vasospastic
ngina, suggesting that eGFR was associated with
he severity of CAD. Finally, the presence of eGFR-
eﬁned CKD as well as diabetes, and no statin use
as associated with maximum 36-month outcomes
n the univariate analysis, in which various risk
actors and baseline medications were assessed.
ultivariate analysis showed that CKD along with
iabetes were independent predictors of secondary
utcomes. The presence of CKD increased the
isk of secondary events including all-cause death
nd cardiovascular events requiring hospitalization,
y 11% compared to the absence of CKD in CAD
atients.
Renal dysfunction is a major limiting factor for
mprovement of long-term prognosis in patients
ith CAD undergoing coronary angioplasty, coro-
ary artery bypass surgery, or medical treatment
11,12]. In general, patients with renal dysfunc-
ion have an increased frequency of comorbidities,
ore severe left ventricular dysfunction, and worse
AD. Irrespective of disease severity or therapeu-
ic strategy, the presence of renal dysfunction
as associated with an increased risk of mor-
ality. Finally, the presence of renal dysfunction
as associated with a differential treatment effect
n survival when comparing coronary angioplasty,
oronary artery bypass surgery, or medical treat-
c
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ent. Although patients with more advanced renal
ysfunction experienced a survival beneﬁt from
oronary artery bypass surgery compared with med-
cal management [13,14], the signiﬁcant beneﬁt of
oronary angioplasty compared with medical man-
gement was lost as renal function declined to the
ost severe range. In this study, 28% of patients
ecruited were treated with coronary angioplasty,
% with bypass surgery, and the remaining 66% were
reated medically. Our study assessed CKD as a
redictor of secondary event occurrence in CAD
atients without regard to the overall treatment
f these patients.
The risk of death associated with renal dys-
unction rises as eGFR declines. Prior data in the
eneral population [15,7] and a recent analysis
f patients with acute myocardial infarction com-
licated by heart failure demonstrated a steep
ise in the risk of death once the eGFR fell to
60ml/min/1.73m2 [16]. Hence, a recent deﬁni-
ion of CKD includes eGFR <60ml/min/1.73m2.
lthough a 10ml/min/1.73m2 rise in eGFR is asso-
iated with an average 20% decrease in the risk of
eath, the impact of a similar difference should
e much greater in patients with CKD. However,
he risk associated with eGFR is non-linear. In our
esults, the cumulative event rate was related to
he stages classiﬁed depending on eGFR, and the
ighest rate as 47% was observed in stage V.
Impaired renal function may increase cardio-
ascular risk in several ways. Renal dysfunction is
ssociated with other disease processes such as
ypertension and diabetes mellitus that are them-
elves determinants of poorer outcome. In addition,
enal dysfunction in association with these factors
mparts a markedly worse prognosis. A declining
FR is also associated with several other factors
hat inﬂuence outcome in cardiac disease such as
mpaired left ventricular systolic function and more
evere symptoms of heart failure. In the recent
ramingham Heart Study data, stage III CKD based
n eGFR was associated with a 20% increased risk
f cardiovascular disease after adjustment for age
nd sex. After accounting for other cardiovascular
isk factors and prevalent cardiovascular disease,
owever, CKD did not constitute a cardiovascular
isease risk equivalent. The association between
KD and cardiovascular disease varied based on
ifferent cardiovascular risk factor combinations
nd was highest in those with diabetes [10]. In
ontrast to risk assessment of primary cardiovas-
ular events in the community-based Framingham
tudy, our study was designed to elucidate the
linical signiﬁcance of eGFR-deﬁned CKD as a pre-
ictor of secondary outcomes of CAD, including
cohort with angiographically veriﬁed CAD. As a
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result, the eGFR-deﬁned CKD was an independent
risk factor for secondary events in patients with
CAD. Considering a mechanistic link between CAD
and CKD in our results, the increased inﬂammation
and oxidative stress, which play an essential role in
the pathophysiology of CAD progression, might be
associated with poorer renal function. In addition,
renal dysfunction may be associated with multiple
other physiological changes, including high levels of
homocysteine, hyperuricemia, hypercalcemia, ane-
mia, and uremia, all of which have detrimental
cardiovascular effects [6]. Certainly, patients with
end-stage renal failure have greatly accelerated
vascular disease and a high cardiac risk [17]. Thus,
renal function integrates the effects of many fac-
tors, all of which affect cardiovascular outcome.
In addition, it has been suggested that, given the
effects of vascular disease on renal function, renal
function may serve as a useful indicator of vascular
health [18].
Since the presence of CKD was shown to con-
tribute to future outcomes in patients with CAD, we
also assessed the inﬂuence of baseline medications
on prognosis in CAD patients with CKD. Our results
showed that baseline use of statins along with RAS
inhibitors such as ACEIs or ARBs reduced risk in all
of the CAD patients, but also in patients with CKD as
well as CAD. Although it has been well established
that statins have anti-atherosclerotic actions that
are both dependent and independent of choles-
terol lowering, there is limited evidence for their
renoprotective action [19]. On the other hand, RAS
inhibition by ACEIs or ARBs is known to protect renal
function [20,21]. Our data suggest that statin use
along with RAS inhibition might be effective for pre-
vention of secondary events in patients with CAD
even in the presence of CKD.
Study limitations
The present study has several possible limitations.
First, our study was cross-sectional with retrospec-
tive data analysis. The eGFR values were assessed
only by a single point measurement at the time
of coronary angiography. To further elucidate the
role of CKD on prognosis of CAD, serial eGFR mea-
surement would be necessary to assess the effects
of various interventions on CKD. Second, in the
present study, we deﬁned CKD according to eGFR
alone. However, a recent deﬁnition of CKD also
includes proteinuria, since the presence of protein-
uria by itself increases the risk of cardiovascular
disease. Although we could not assess proteinuria
in this study, the use of both eGFR and proteinuria
might lead to a more accurate classiﬁcation of CKD.K. Matsuo et al.
inally, we also assessed the effects of medications
n long-term prognosis. However, our assessment
ncluded only baseline medications. Newly pre-
cribed agents during the follow-up term that might
ontribute to prognosis were not considered in the
resent study.
onclusion
GFR-deﬁned CKD appears to be a strong predictor
f secondary events in Japanese patients with CAD.
n addition, anti-atherosclerotic therapies under
GFR monitoring to consider renoprotection by
tatins and/or RAS inhibitors would be an impor-
ant strategy to improve long-term prognosis in
apanese CAD patients.
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